ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0601

Racial Differences in Medication Beliefs Among SLE Patients

D Ryan Anderson1, Amanda Eudy2, Megan Clowse3, Rebecca Sadun2, Jennifer Rogers2, Lisa Criscione-Schreiber4, Jayanth Doss2, Corrine Volis5, Theresa Coles2 and Kai Sun2, 1Duke University Hospital, Durham, NC, 2Duke University, Durham, NC, 3Duke University, Chapel Hill, NC, 4Duke University School of Medicine, Durham, NC, 5University of Wisconsin School of Medicine and Public Health, Madison, WI

Meeting: ACR Convergence 2021

Keywords: Disparities, health behaviors, Minority Health, race/ethnicity, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 7, 2021

Title: Healthcare Disparities in Rheumatology Poster (0594–0622)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: Medication adherence is essential to establishing and maintaining disease remission among SLE patients. Patients’ beliefs about treatment influence engagement and adherence to therapy. We previously found racial disparities in medication adherence between White and non-White SLE patients, but racial differences in beliefs about medications have not been well explored. In this study, we investigated differences in medication beliefs and their association with medication adherence between White and non-White SLE patients.

Methods: Patients meeting ACR or SLICC SLE criteria completed the 18-item Beliefs about Medicines Questionnaire (BMQ), which measures four belief domains: disease-specific medication necessity, disease-specific medication concern, general medication overuse, and general medication harm. Adherence was measured using the Domains of Subjective Extent of Nonadherence (DOSE- nonadherence) questionnaire. Due to small numbers of patients who identified as Asian and Hispanic, they were grouped with Black patients and analyzed as non-White. We compared median BMQ scores between White and non-White patients, and explored differences in BMQ scores between adherent and non-adherent patients by race.

Results: This analysis included 102 patients (48 White, 48 Black, 5 Asian, 1 Hispanic, mean age 50, 96% female, 33% < college education, 54% private insurance). For the 18 individual questions, 11 produced answers that were statistically different between the White and non-White patients. Compared to Whites, non-White patients had more general beliefs that medications are harmful (8.5 [interquartile range (IQR) 7-10] vs 7 [IQR 5-9], p=0.005) and overused (11 [IQR 9-12] vs 8.5 [IQR 8-10], p=0.003).

While 71% of White patients reported adherence, only 44% of non-White patients reported adherence. Among White patients, those who were nonadherent reported more SLE-specific medication concerns. In contrast, among non-White patients, those who were non-adherent reported more general beliefs that medications are harmful and overused (Table 1).

Conclusion: We found significant differences in medication beliefs between White and non-White SLE patients with the greatest difference in general beliefs about medications. These racial differences in medication beliefs were also present in adherence data, with non-adherence in the White group being driven by specific concerns about SLE medications while non-adherence in the non-White group was driven by general concerns about medications. These results suggest adherence interventions tailored to race may be more effective, with a focus on building trust in the non-White community. Future studies should investigate the relationship between medication beliefs and SLE outcomes. The extent to which racial differences in medication beliefs may be driven by mistrust in the medical system and systemic racism also deserves further study.

Table 1.comparing BMQ domains between adherent and non-adherent patients by race.


Disclosures: D. Anderson, None; A. Eudy, NIH NCATS Award Number 1KL2TR002554, 5, Pfizer, 5, Exagen, 5; M. Clowse, UCB Pharma, 2, Pfizer, 5, GSK, 2, 5; R. Sadun, None; J. Rogers, Exagen, 2, 5, Pfizer, 5, Eli Lilly, 2, Immunovant, 2, Northwestern University, 2; L. Criscione-Schreiber, GlaxoSmithKline, 5; J. Doss, Pfizer, 5; C. Volis, None; T. Coles, Merck, 5; K. Sun, None.

To cite this abstract in AMA style:

Anderson D, Eudy A, Clowse M, Sadun R, Rogers J, Criscione-Schreiber L, Doss J, Volis C, Coles T, Sun K. Racial Differences in Medication Beliefs Among SLE Patients [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/racial-differences-in-medication-beliefs-among-sle-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/racial-differences-in-medication-beliefs-among-sle-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology